James Brent Page
Physician at Hayford Ave, Laramie, WY
License number
Colorado 38035
Issued Date
Jul 22, 1999
Renew Date
Jun 1, 2009
Expiration Date
May 31, 2011
Type
Physician
Address
Address
3120 Hayford Ave, Laramie, WY 82072
Professional information
See more information about James Brent Page at trustoria.com
Dr. James B Page, Laramie WY - MD (Doctor of Medicine)
Dr. James B Page, Laramie WY - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry)
Address:
PATHWAYS INC
1465 N 4Th St SUITE 119, Laramie 82072
(307) 721-0700 (Phone)
1465 N 4Th St SUITE 119, Laramie 82072
(307) 721-0700 (Phone)
Certifications:
Psychiatry, 2005
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
PATHWAYS INC
1465 N 4Th St SUITE 119, Laramie 82072
Ivinson Memorial Hospital
255 North 30Th St, Laramie 82072
1465 N 4Th St SUITE 119, Laramie 82072
Ivinson Memorial Hospital
255 North 30Th St, Laramie 82072
Education:
Medical School
University of Colorado At Denver
Graduated: 1997
University of Colorado At Denver
Graduated: 1997
James B. Page, Laramie WY - Lawyer
James B. Page, Laramie WY - Lawyer
Office:
3120 Hayford Ave, Laramie, WY
ISLN:
922633875
Admitted:
1991
Cicletanine And Pkc Inhibitors In The Treatment Of Pulmonary And Cardiac Disorders
Cicletanine And Pkc Inhibitors In The Treatment Of Pulmonary And Cardiac Disorders
US Patent:
2008031, Dec 18, 2008
Filed:
Jan 3, 2008
Appl. No.:
12/006825
Inventors:
Glenn V. Cornett - Palo Alto CA, US
James Page - Laramie WY, US
Wayne A. Jones - Palo Alto CA, US
Karen Page - Laramie WY, US
James Page - Laramie WY, US
Wayne A. Jones - Palo Alto CA, US
Karen Page - Laramie WY, US
Assignee:
Gilead Sciences, Inc. - Foster City CA
International Classification:
A61K 31/4985, A61K 31/4355, A61K 31/192, A61K 31/195, A61P 9/10, A61K 31/34, A61K 31/407, A61K 31/343
US Classification:
514249, 514302, 514571, 514410, 514469, 514470
Abstract:
Embodiments of the present invention are related to novel therapeutic drugs, drug combinations, and associated methods for treating or preventing pulmonary disease, including pulmonary hypertension, pulmonary fibrosis, asthma and COPD, and heart failure, together with other pulmonary and cardiovascular diseases and their complications. More particularly, aspects of the present invention are related to the use of cicletanine and ruboxistaurin as monotherapies or in combination with other agents for treatment of disease. Cicletanine may be used as pure (+) or (−) enantiomers or as a racemic or non-racemic mixture of those enantiomers.